Postmenopausal Osteoporosis Treatment

Global Postmenopausal Osteoporosis Treatment Market to Reach US$12.4 Billion by 2030

The global market for Postmenopausal Osteoporosis Treatment estimated at US$9.8 Billion in the year 2024, is expected to reach US$12.4 Billion by 2030, growing at a CAGR of 4.0% over the analysis period 2024-2030. Bisphosphonates, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Vitamin D3 segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 7.5% CAGR

The Postmenopausal Osteoporosis Treatment market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 7.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Postmenopausal Osteoporosis Treatment Market – Key Trends & Drivers Summarized

Why Is Postmenopausal Osteoporosis Treatment Essential for Aging Populations?

Postmenopausal osteoporosis (PMO) is a progressive bone disease that affects millions of women worldwide due to estrogen deficiency following menopause, leading to increased bone fragility and fracture risk. With aging populations and longer life expectancy, postmenopausal osteoporosis has become a major public health concern, particularly in North America, Europe, and Asia-Pacific, where a rising number of postmenopausal women are at risk of osteoporotic fractures. The condition significantly impacts mobility, independence, and healthcare costs, driving the demand for effective and innovative osteoporosis treatments.

The increasing prevalence of osteoporosis-related fractures, especially hip, spine, and wrist fractures, has led to a greater focus on early diagnosis, prevention, and treatment. As awareness of bone health and fracture prevention grows, more women are seeking medical intervention through pharmacological therapies, lifestyle modifications, and advanced bone health monitoring technologies. The market for postmenopausal osteoporosis treatments is expanding due to improved screening programs, government healthcare initiatives, and advancements in drug development.

How Are Technological Advancements Improving Osteoporosis Treatment Options?

Innovations in pharmacology, biotechnology, and digital health solutions are transforming the management of postmenopausal osteoporosis, making treatments more effective, personalized, and convenient. One of the most significant advancements is the development of next-generation osteoporosis drugs, including monoclonal antibodies, selective estrogen receptor modulators (SERMs), and bone-forming agents that offer better fracture protection and improved patient adherence.

Among the latest breakthroughs, monoclonal antibody therapies such as Denosumab (Prolia) and Romosozumab (Evenity) are changing the treatment landscape by providing targeted inhibition of bone resorption and enhanced bone formation. These biologic agents offer superior efficacy compared to traditional bisphosphonates, reducing the risk of vertebral and non-vertebral fractures with convenient injection-based dosing schedules. Similarly, the development of anabolic agents like Teriparatide (Forteo) and Abaloparatide (Tymlos) has introduced new treatment options for high-risk patients requiring accelerated bone regeneration.

The rise of digital health and wearable technology is also revolutionizing osteoporosis management. Smart health monitoring devices, including bone density tracking apps, AI-driven fracture risk assessment tools, and remote patient monitoring systems, are helping physicians tailor personalized treatment plans based on real-time bone health data. Additionally, telemedicine and virtual consultations are making osteoporosis care more accessible, particularly for elderly patients in rural and underserved regions.

What Market Trends Are Driving the Growth of Postmenopausal Osteoporosis Treatment?

One of the most prominent trends in the postmenopausal osteoporosis treatment market is the increasing adoption of biologics and targeted therapies. With growing concerns about long-term bisphosphonate use and its potential risks, such as atypical fractures and osteonecrosis of the jaw (ONJ), many healthcare providers are transitioning patients to novel biologic treatments with superior safety profiles. This shift is driving strong market growth in the monoclonal antibody and anabolic drug segments.

The integration of artificial intelligence (AI) and machine learning (ML) in osteoporosis diagnostics is another key trend influencing the market. AI-powered bone health screening algorithms and predictive analytics are enabling early detection of osteoporosis by analyzing bone mineral density (BMD) scans, genetic markers, and patient lifestyle data. This advancement is facilitating proactive treatment initiation and personalized therapy adjustments, improving patient outcomes and adherence rates.

Another significant trend is the emphasis on combination therapies and multi-target treatment strategies. Researchers are exploring new drug combinations that enhance both bone resorption inhibition and bone formation stimulation, offering greater fracture protection than monotherapy. Additionally, the increasing use of vitamin D and calcium supplementation, along with pharmacological treatments, is improving treatment effectiveness and patient compliance.

The expansion of osteoporosis awareness programs and government healthcare policies is also shaping market growth. Many countries are implementing fracture liaison services (FLS) and osteoporosis screening programs to ensure early detection and treatment of at-risk women. Reimbursement policies and insurance coverage expansions for osteoporosis medications and bone health screenings are further encouraging higher treatment adoption rates.

What Factors Are Driving the Growth of the Postmenopausal Osteoporosis Treatment Market?

The growth in the postmenopausal osteoporosis treatment market is driven by several factors, including an aging global population, rising fracture incidence, and advancements in drug therapies. One of the primary drivers is the growing number of postmenopausal women worldwide, particularly in regions with rapidly aging demographics, such as Japan, China, the U.S., and Europe. With one in three women over the age of 50 estimated to suffer from an osteoporosis-related fracture, the demand for preventive and therapeutic interventions is accelerating.

Another major growth factor is the expansion of research and development (R&D) in osteoporosis drug discovery. Pharmaceutical companies are heavily investing in new-generation osteoporosis drugs, including dual-action therapies, stem cell-based bone regeneration treatments, and gene-targeted medications that promise higher efficacy with fewer side effects. The introduction of biosimilars for osteoporosis treatments is also making advanced therapies more affordable and accessible, increasing market penetration in developing economies.

The rising adoption of digital health solutions for osteoporosis management is contributing to market expansion. The availability of mobile health (mHealth) apps, wearable bone density monitors, and AI-driven risk assessment tools is empowering patients and physicians to track and manage osteoporosis more effectively. Additionally, telehealth services and remote patient monitoring programs are making osteoporosis care more accessible, particularly in regions with limited healthcare infrastructure.

Lastly, the increasing awareness of osteoporosis prevention and lifestyle interventions is driving early treatment adoption. Public health campaigns promoting weight-bearing exercises, nutritional supplementation, and lifestyle modifications are encouraging women to seek early osteoporosis screenings and preventive treatments. With the growing recognition of osteoporosis as a serious chronic condition, healthcare providers are prioritizing proactive bone health management, boosting long-term demand for osteoporosis therapies.

As the burden of osteoporosis continues to rise, the postmenopausal osteoporosis treatment market is expected to expand, driven by biologic drug advancements, digital health innovations, and global initiatives for fracture prevention and early intervention.

SCOPE OF STUDY:

The report analyzes the Postmenopausal Osteoporosis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Treatment Type (Bisphosphonates, Vitamin D3, Estrogen Agonist / Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy, Other Treatment Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Allergan plc
• Amgen Inc.
• Cipla Inc.
• Daiichi Sankyo Company, Limited
• Eisai Co., Ltd.
• Eli Lilly and Company
• Entera Bio Ltd.
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Radius Health, Inc.
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Ltd.
• Teva Pharmaceutical Industries Ltd.
• UCB S.A.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.